Novel Imidazoquinoline Based TLR7 Agonist Induces Antileishmanial Efficacy‐An In Vitro Study
Drug Development Research · 2026
DOI: 10.1002/ddr.70250 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, 2026. Verfasst von Shivani Thakur und 6 weiteren Autor:innen. Beteiligte Einrichtung: Parasitology Laboratory, Department of Zoology, Panjab University, Chandigarh, India. Hauptthemen laut MEDLINE: Toll-Like Receptor 7, Leishmania donovani, Quinolines, Antiprotozoal Agents. Die Arbeit nennt 37 Literaturangaben. Gefördert von: Council of Scientific and Industrial Research, ICMR (Indian Council of Medical Research), New Delhi, India, Council of Scientific and Industrial Research, India.
Abstract (Originalsprache)
Leishmaniasis elimination and control remain challenging due to the lack of successful treatment and possible prevention. A suitable anti‐leishmanial medication that is acceptable in terms of price and safety is currently being researched. In light of this, the current study examined the effectiveness of imidazoquinoline based selective Toll‐like receptor (TLR)‐7 agonists as anti‐leishmanial agents. A library of TLR7 agonists was evaluated for anti‐leishmanial efficacy against experimental visceral leishmaniasis (VL). Among all the agonists, 2‐butyl‐1‐(3,4‐dimethoxybenzyl)‐1 H ‐imidazo[4,5‐ c ]quinolin‐4‐amine ( 7 ) and its niosomal formulation 18 exhibited better activity than Miltefosine. These were then further studied against Leishmania donovani for their ability to arrest the parasites at sub G 0 /G 1 phase of cell cycle. The selected TLR7 agonists depicted their ability to arrest higher percentage of parasites in comparison to the standard antileishmanial drugs. Similar observations were seen in case of reactive oxygen species (ROS) generation where parasites treated with the lead TLR7 agonist produced higher ROS than the untreated parasites. These results suggest that TLR7 agonist 7 and its niosomal formulation 18 could be the promising hits for development of a novel drug treating VL. However additional in‐vivo studies could aid in their future advancement.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Parasitology Laboratory, Department of Zoology, Panjab University, Chandigarh, India.
- Department of Chemistry, Centre of Advanced Studies in Chemistry, Panjab University, Chandigarh, India.
- National Interdisciplinary Centre of Vaccine, Immunotherapeutics and Antimicrobials, Panjab University, Chandigarh, India.
- Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research, Mohali, Punjab, India.
ORCID-Profile: Sukhbir Kaur
Förderung
- Council of Scientific and Industrial Research
- ICMR (Indian Council of Medical Research), New Delhi, India
- Council of Scientific and Industrial Research, India
Zitieren
APA
Thakur, S., Kumar, K., Kaur, S., Sanjana, Sihag, B., Salunke, D. B., & Kaur, S. (2026). Novel Imidazoquinoline Based TLR7 Agonist Induces Antileishmanial Efficacy‐An In Vitro Study. Drug Development Research. https://doi.org/10.1002/ddr.70250
Vancouver
Thakur S, Kumar K, Kaur S, Sanjana, Sihag B, Salunke DB, et al. Novel Imidazoquinoline Based TLR7 Agonist Induces Antileishmanial Efficacy‐An In Vitro Study. Drug Development Research. 2026. doi:10.1002/ddr.70250
BibTeX
@article{Thakur2026,
author = {Thakur, Shivani and Kumar, Kushvinder and Kaur, Sandeep and Sanjana and Sihag, Binita and Salunke, Deepak B and Kaur, Sukhbir},
title = {Novel Imidazoquinoline Based TLR7 Agonist Induces Antileishmanial Efficacy‐An In Vitro Study},
journal = {Drug Development Research},
year = {2026},
doi = {10.1002/ddr.70250}
}
EUVIMED